Felix Tells Existing Patients: Auto-Switch to Lower Generic Price

Felix's auto-switch policy

In its updated waitlist FAQ, Felix states that patients currently prescribed Ozempic through the platform need no action when generic semaglutide arrives, because "the price of Ozempic is expected to drop to more closely align with the price of generic semaglutide" and existing patients "will automatically be charged the new lower price" on their next fill [Source: felixforyou.ca/generic-semaglutide-waitlist].

Felix says it expects to make generic semaglutide available to its patients "in the coming weeks" following Health Canada's authorization [Source: felixforyou.ca/generic-semaglutide-waitlist].

The pricing framework Felix is citing

Felix's projections are anchored to the Pan-Canadian Pharmaceutical Alliance generic pricing framework. Based on a stated current brand price of $320 per pen, the company outlines three tiers [Source: felixforyou.ca/generic-semaglutide-waitlist]:

• 1 generic available: approximately $240 per pen, around 75% of brand price
• 2 generics available: approximately $160 per pen, around 50% of brand price
• 3 or more generics available: approximately $112 per pen, around 35% of brand price

The company notes that "increased competition typically drives costs down across both brand-name and generic medications, and similar launches have seen prices drop by up to 65%" [Source: felixforyou.ca/generic-semaglutide-waitlist]. Felix's $320 reference price sits within the current pharmacy range tracked on GLP1Prices.ca for Ozempic, which spans CAD $222 to $663 across Canadian pharmacies.

Regulatory backdrop

Health Canada authorized the first generic semaglutide injection on April 28, 2026, a submission filed by Dr. Reddy's Laboratories and a generic version of the brand-name drug Ozempic [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. The regulator described the approval as a G7 first and confirmed that eight other generic semaglutide submissions from different companies remain under review, with decisions expected "in the coming weeks and months" [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html].

Felix's communication notes that production scale-up may take time and that "availability could be limited at first or sporadic throughout the year depending on demand and production capacity" [Source: felixforyou.ca/generic-semaglutide-waitlist]. The company also flags that "coverage under provincial drug plans will vary by province and is not yet confirmed" [Source: felixforyou.ca/generic-semaglutide-waitlist].

What CMA tells patients about switching

The Canadian Medical Association's patient guidance similarly indicates that in many cases a prescriber can allow the pharmacy to switch a patient to a generic, and that if an insurance plan already approved Ozempic, "it will usually cover the generic automatically once it's available" [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada]. The CMA adds that patients who choose to stay on the brand-name drug will typically be asked by their plan to pay the price difference out of pocket [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada].

The CMA also notes that as of late December 2025, Health Canada had nine active applications from companies seeking to sell generic semaglutide [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada].

Scope of the price change

Felix is explicit that the price changes apply only to semaglutide products. "Because only semaglutide is going off-patent, lower prices are expected for semaglutide medications, but not necessarily others" [Source: felixforyou.ca/generic-semaglutide-waitlist]. That distinction matters for patients tracking Mounjaro and Zepbound, which contain tirzepatide rather than semaglutide and are not affected by the current generic approvals.

Obesity Canada's Dr. Sanjeev Sockalingam, Scientific Director, framed the approval as a regulatory milestone that should "prompt governments, insurers, and employers to reconsider how obesity treatment is covered within these systems," noting that "fewer than 20 per cent of Canadians with private drug benefit plans have access to Health Canada-approved obesity treatment medications" [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Patients tracking pharmacy-level pricing can consult our generic semaglutide tracker, the insurance coverage checker, or the FAQ for additional context. Listings for Wegovy and Rybelsus reflect current verified pharmacy prices.